I ntercellular communication is essential for immune cells to coordinate inflammatory responses. Cytokines, chemokines and cell surface receptors are well-known mediators of this process. In addition to these classical signalling molecules, emerging evidence suggests that immune cells can signal by secreting small lipid packages called exosomes, which carry a variety of different molecules that can be taken up by recipient cells [1] [2] [3] [4] . The functional relevance of exosomes in many different biological systems, including the immune system, is beginning to be demonstrated [5] [6] [7] [8] [9] [10] [11] .
MicroRNAs (miRNAs) are important modulators of gene expression that function by targeting messenger RNAs for degradation or preventing translation. Typically, miRNAs are thought to function within the cells in which they are made; however, recently, miRNAs have been observed in secreted exosomes [12] [13] [14] . Immune cells, including antigen-presenting dendritic cells (DCs) and T lymphocytes, can both secrete and take up exosomal miRNAs, suggesting that exosomal transfer of miRNAs could be a novel mechanism for intercellular communication 12, 14, 15 . Furthermore, recent studies indicate that the loading of miRNAs into exosomes is a selective process where specific motifs in miRNA sequences are recognized by the RNA-binding protein, hnRNPA2B1 (ref. 16 ). Other reports find that miRNA loading into exosomes is dependent on 3 0 -end uridylated isoforms 17 and on the levels of miRNA targets in producer cells 18 . Consistent with this, exosomal miRNA signatures do not simply reflect the miRNA composition of the parent cell, but are composed of a distinct set of miRNAs 16, [18] [19] [20] [21] . This argues that certain miRNAs have evolved to be packaged into exosomes to carry out their biological functions.
Exosomally transferred miRNAs are emerging as novel regulators of cellular function. There is evidence in both immune cells and other cell types that transferred miRNAs repress target mRNAs in recipient cells [12] [13] [14] [22] [23] [24] . The transfer of miRNAs can also cause physiological changes in recipient cells [5] [6] [7] , as demonstrated by miRNAs moving from cancer cells to endothelial cells, which promotes tumour metastasis 5 . Cancer cells can also receive exosomal miRNAs secreted from immune cells, which were shown to have an anti-proliferative effect on the tumour cells 7 . These data suggest that different cell types can secrete or receive miRNAs as a form of communication and have set the stage for investigating the functional roles of transferred miRNAs in the context of immune responses.
Within the immune system, several specific miRNAs have recently emerged as important regulators of immune cell function. Among these, miR-155 is a promoter of inflammatory responses, while miR-146a is a mediator of immune suppression [25] [26] [27] [28] . Despite significant progress in our understanding of how these miRNAs influence immunity in vivo, there are many aspects of their regulation and function that remain unclear. In the current study, we investigate whether endogenous miR-155 and miR-146a are functionally transferred between primary bone marrow-derived DCs (BMDCs). We find that both of these miRNAs are released within exosomes and are taken up by recipient BMDCs. On uptake, the miRNAs are associated with Ago proteins, knock down their respective targets and reprogramme the response of BMDCs to endotoxin challenge. We also show that miR-155 can be transferred between immune cells in vivo. Finally, we demonstrate that injection of miR-146a-containing exosomes into mice inhibits their inflammatory response to endotoxin, whereas injection of miR-155-containing exosomes promotes inflammation following exposure to the same inflammatory stimulus. Our study supports a model whereby exosomal miRNAs participate in the regulation of inflammatory responses.
Results miR-155 is found in exosomes and transferred between BMDCs. miR-155 is an immunomodulatory miRNA expressed by many types of immune cells including DCs 27 . We sought to determine whether miR-155 could be passed between cultured BMDCs. Cocultures of primary mouse BMDCs derived from CD45.1 þ Wt mice and CD45.2 þ miR-155 À / À mice were set up at a 1:1 ratio with and without lipopolysaccharide (LPS) treatment (Fig. 1a) . As a control, miR-155 À / À BMDCs were also cultured under the same conditions without Wt cells. After 24 h, the co-cultured Wt and miR-155 À / À CD11c þ BMDCs were separated based on their differential CD45 markers using fluorescence-activated cell sorting (FACS) (Fig. 1b) . Quantitative reversetranscriptase-PCR (qRT-PCR) was performed on RNA isolated from the CD45.2 þ miR-155 À / À BMDCs. miR-155 was detected in miR-155 À / À BMDCs that were cultured with Wt cells and the signal was clearly above background levels established using miR-155 À / À BMDCs cultured alone (Fig. 1c) . When cells were treated with LPS, the transfer of miR-155 to miR155 À / À cells was increased, consistent with previous findings that cellular miR-155 concentrations are elevated following LPS stimulation 29 (Fig. 1c) .
To determine whether cell-cell contact is necessary for the transfer of miR-155, we used 0.4-mm filters to separate miR-155 À / À and Wt BMDCs that were co-cultured in the presence or the absence of LPS for 24 h. The 0.4-mm pore size allows for small molecules and vesicles such as exosomes to pass through but prevents cell-contact-mediated exchange of material 23 . We detected miR-155 in the miR-155 À / À BMDCs that were cultured with Wt BMDCs, which was above background (Fig. 1d) . Our data indicate that miR-155 is passed between cells, and that cell-cell contact is not necessary for transfer to occur between BMDCs.
As miRNAs have recently been shown to be transferred between immune cells within exosomes, we investigated whether miR-155 is contained within these secreted vesicles. To address this question, we isolated the exosomal pellet from Wt or miR-155 À / À BMDC conditioned media using differential centrifugation. Both electron microscopy (EM) and a CD63 western blotting of the isolated vesicles indicated that we had successfully isolated exosomes (Fig. 1e,f) . Using qRT-PCR, we found that miR-155 was contained in exosomes derived from Wt BMDCs but not in exosomes derived from miR-155 À / À cells (Fig. 1g ). BMDCs treated with LPS enhanced the levels of miR-155 found in the exosomal pellet, consistent with higher levels of miR-155 being produced by the activated BMDCs. In addition, we blocked exosome formation by treating donor BMDCs with GW4869, a drug that hinders exosome biogenesis by blocking neutral sphingomyelinase 2 (nSMase2) (refs 13,15) . Following drug treatment, the pellet contained significantly reduced exosomes as determined by EXOCET quantification (Fig. 1h) , CD63 western blotting and EM ( Supplementary Fig. 1 ). Drug treatment also prevented the detection of miR-155 in the exosomal pellet (Fig. 1i) , suggesting that miR-155 is contained within exosomes. In addition, we derived BMDCs from Rab27a and Rab27b double-knockout mice (Rab27 DKO), which have been previously shown to have decreased release of exosomes 23 . We found that Rab27 DKO BMDCs had both decreased exosome release (Fig. 1j ) and a corresponding decrease in miR-155 in the exosomal pellet (Fig. 1k) . Together, these data show that miR-155 can be passed between BMDCs, and that miR-155 is contained in exosomes produced by BMDCs.
Exosomal transfer of miR-155 is functionally relevant. With the knowledge that miR-155 can be transferred between BMDCs, we wanted to determine whether exosomes are sufficient for this ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8321 transfer and whether transfer could result in knockdown of target mRNAs. To specifically investigate the impact of exosomally transferred miRNA without the effects of other factors that are released from BMDCs, we purified exosomes away from other components in the conditioned medium using differential centrifugation and washing. Next, the exosomes were re-suspended in fresh medium and administered to recipient cells. Wt (1 Â 10 6 ) or miR-155 À / À BMDCs produced B5 Â 10 8 exosomes in 24 h (Supplementary Fig. 2 ). Exosomes isolated from the supernatant of both Wt and miR-155 À / À BMDCs treated with GW4869 or dimethylsulfoxide vehicle control were transferred to miR-155 À / À receipient BMDCs. miR-155 À / À recipient BMDCs were incubated with donor exosomes for 24 h, to allow time for miRNA transfer and knockdown of miRNA targets (Fig. 2a) . Using qRT-PCR, we detected increased miR-155 levels and decreased mRNA levels of miR-155 targets BACH1
and SHIP1 when cells were treated with Wt exosomes (Fig. 2b-d) . These changes were prevented if the exosomes were derived from miR-155 À / À BMDCs, or if the Wt donor cells were pretreated with GW4869. SHIP1 protein levels were also decreased in miR-155 À / À BMDCs that received Wt exosomes (Fig. 2e,f miR-155 À / À recipient cells to B20% of Wt miR-155 levels ( Supplementary Fig. 3a,b) . Furthermore, we also looked at the relative expression of a separate miRNA, miR-425, which has been previously seen to be released in exosomes 30 , as a control. The levels of miR-425 increased with exosome delivery and were roughly the same in Wt and knockout groups ( Supplementary  Fig. 3c,d ).
In addition to using miR-155 À / À recipient cells, which provide a clean background to clearly detect the transferred miRNA, we also examined whether transferred miR-155 could be detected in Wt BMDC recipients. miR-155 levels were increased on treatment of Wt BMDCs with Wt exosomes but were not increased when treated with miR-155 À / À exosomes (Fig. 2g) . In addition, the mRNA levels of both BACH1 and SHIP1 were decreased in Wt BMDCs receiving exosomal miR-155 (Fig. 2h,i) . These data indicate that miR-155 can be transferred between Wt BMDCs in exosomes, resulting in the knockdown of known miR-155 targets.
As we have found that miR-155 can knock down its targets in recipient cells, we next investigated whether the transfer of miR-155 alters downstream factors in recipient cells. We found that exosomal miR-155 increased the expression of HO1 (Fig. 2j) , an oxidative stress response gene that is well known to be repressed by BACH1, a gene we have shown is targeted by transferred miR-155 (ref. 29 ; Fig. 2c ). These results indicate that transferred miR-155 not only represses its putative direct targets but can also affect factors that are downstream of these targets.
To further characterize the functional transfer of miR-155 between BMDCs, we examined whether transferred miR-155 is associated with AGO proteins that are essential for miRNAmediated knockdown of targets. Following exosomal transfer of miR-155 into miR-155 À / À BMDCs, an AGO immunoprecipitation (IP) was performed using a pan-AGO antibody and western blotting for AGO2 was preformed to verify pulldown was occurring. Using qRT-PCR, we found that miR-155 is associated with AGO proteins in miR-155 À / À recipient cells (Fig. 2k,l) . We did not detect miR-155-associated AGO proteins when miR-155 À / À BMDCs were treated with miR-155 À / À exosomes. Further, AGO2 was not detected via western blotting and miR-155 was not pulled down when an isotype control antibody was used. As an additional control, we found that another miRNA, miR-146a, was also enriched in the AGO pulldown from both groups (Fig. 2m ). These data demonstrate that exosomal miR-155 is associated with AGO proteins, key components of the RNAinduced silencing complex (RISC) complex, following its uptake by recipient BMDCs.
Exosomal transfer of miR-146a is functionally relevant. miR-146a is an important anti-inflammatory miRNA involved in DC function 27 and plays an opposing role to miR-155 during inflammatory responses 25, 31 . We wanted to determine whether miR-146a was also contained in BMDC-derived exosomes; hence, we isolated exosomes from Wt BMDCs that had been treated with or without GW4869 and/or LPS, and found that miR-146a was contained in exosomes from untreated BMDCs but was not present in the exosomal pellet from BMDCs treated with GW4869 (Fig. 3a) . miR-146a is marginally increased in exosomes from BMDCs treated with LPS. In addition, reductions in miR-146a were observed in the extracellular exosomal fraction obtained from Rab27 DKO BMDCs compared with Wt controls (Fig. 3b) . These data reveal that miR-146a is contained within exosomes released from BMDCs.
To test whether miR-146a could be functionally transferred between BMDCs, we isolated exosomes from Wt or miR-146a À / À BMDCs and administered them to miR-146a À / À BMDCs (Fig. 3c ). Similar to miR-155, we observed that exosomal miR-146a was taken up by recipient BMDCs (Fig. 3d) , and that miR-146a targets, IRAK1 and TRAF6, were repressed in recipient BMDCs receiving Wt but not miR-146a À / À exosomes looking at both the mRNA and protein levels ( Fig. 3e-j) . In addition, we calculated miR-146a copy number in Wt and miR-146a À / À exosomes where we found approximately one copy of miR-146a per exosome (Fig. 3k) . miR-146a copy number was also calculated in Wt and miR-146a À / À donor BMDCs and BMDCs that received either Wt or miR-146a À / À exosomes (Fig. 3l) . We observed an average of 370 copies present in recipient BMDCs following exosomes treatment. It has been suggested that 100-1,000 copies of miRNA per cell is likely to be functionally relevant 32 . As a control, we investigated the relative expression of miR-425, which was similar between the genotypes ( Supplementary Fig. 3e ,f). Our copy number data along with our observations of target knockdown are consistent with exosomally transferred miR-146a having functional relevance.
Recently, it has been shown in human B-cell lines that miRNAs are selectively packaged into exosomes based on 3 0 -nontemplated nucleotide additions (NTAs) 17 where 3 0 -uridylation was enriched in miRNAs contained in exosomes and 3 0 -adenylation was enriched in miRNAs retained in cells. To address whether we observe a similar phenomenon, RNA sequencing was performed using RNA from Wt donor BMDCs and miR-155 and miR-146a DKO BMDCs that had received Wt exosomes. Next, we used a previously reported approach to identify NTAs in our data set 17 . However, we did not observe an enrichment of 3 0 -uridylation in transferred miR-155 or miR-146a ( Supplementary Fig. 4 ). This difference from previous findings could be due to species and cellular differences (mouse primary BMDCs versus human B-cell lines) or further processing of the transferred miRNAs in recipient cells. However, we did observe some differences at certain nucleotide positions in each respective mature miRNA sequence when comparing Wt donor BMDCs with DKO BMDCs that received Wt exosomes (Supplementary  Tables 1 and 2 ). These results are consistent with the idea that alterations to the mature miRNA sequence may influence miRNA loading into exosomes versus cellular retention. Seed-dependent repression of miRNA targets. We next determined whether miR-155 and miR-146a mimic-loaded exosomes were sufficient to mediate direct target knockdown in recipient cells. miR-155 À / À or miR-146a À / À BMDCs were transfected with either corresponding miRNA mimics, scrambled miRNA mimics, or seed mutant miRNA mimics for 24 h, then washed three times with PBS to remove any mimics that did not make it into the cells (Fig. 4a) . We isolated exosomes from the cells after 24 h and transferred them to recipient knockout BMDCs. After 24 h, RNA was isolated from the cells and qRT-PCR was performed to assay the delivery of mimics and the knockdown of target mRNAs. We found that miRNA mimics could be successfully loaded into exosomes and delivered to recipient cells ( Supplementary Figs 5 and 6 ). The transfer of miRNA mimics containing exosomes resulted in knockdown of respective target mRNAs in recipient BMDCs (Fig. 4b-f ). However, exosomes that did not carry mimics, or that carried scrambled or seed mutant mimics, caused no change in target mRNA expression in recipient cells. These results indicate that exosomal miRNAs are responsible for direct target repression and are able to complement the target knockdown phenotype.
To further assess whether exosomal miRNA target repression was direct, we used 3 0 -untranslated region (UTR) luciferase reporter assays. Knockout BMDCs were transfected with 3 0 -UTR luciferase reporters for 6 h followed by treatment with or without Wt exosomes (Fig. 4g) . miR-155 À / À BMDCs were transfected with either a pmiReport empty vector control, BACH1 3 0 -UTR, BACH1 miR-155-binding site (bs) mutant 3 0 -UTR, or a miR-155-positive control (2mer). Luciferase activity in cells receiving the BACH1 3 0 -UTR or 2mer reporter constructs was reduced in response to miRNAs delivered by exosomes, while the exosomal miRNAs had little impact on luciferase activity in cells receiving the pmiReport empty vector or the BACH1 miR-155 bs mutant 3 0 -UTR reporter (Fig. 4h) . In a separate experiment, miR-146a À / À BMDCs were transfected with either a pmiReport empty vector control, TRAF6 3 0 -UTR, or a TRAF6 miR-146a bs mutant 3 0 -UTR. The BMDCs transfected with the TRAF6 3 0 -UTR had decreased luciferase activity compared with the pmiReport empty vector and the TRAF6 miR-146a bs mutant 3 0 -UTR following exosome delivery of miRNAs (Fig. 4i) . These results indicate that exosomally transferred miRNAs directly repress their targets via direct 3 0 -UTR interactions.
Exosomal miR-155 and miR-146a modulate the response to LPS. To determine whether the transfer of miR-155 via exosomes could affect the BMDC response to LPS, exosomes were isolated from Wt or miR-155 À / À BMDCs and transferred to miR-155 À / À BMDCs. Twenty-four hours later, cells were treated with LPS for 6 h (Fig. 5a ). Consistent with a previously reported role for miR-155 in promoting interleukin (IL)-6 expression 33 and previously reported roles of miR-155-regulated responses to endotoxin 34 , cells that were treated with miR-155-containing exosomes produced more IL-6 on treatment with LPS for 6 h than cells having received miR-155 À / À exosomes (Fig. 5b) . These findings indicate that exosomes containing miR-155 can reprogramme recipient BMDCs in a manner that enhances their response to LPS. miR-146a is known to induce an anti-inflammatory response to LPS 26 . Therefore, we wanted to investigate whether exosomally transferred miR-146a can programme BMDCs to respond in an anti-inflammatory manner, using a similar experimental setup as we did for miR-155 (Fig. 5c) . BMDCs pre-treated with Wt exosomes produced more IL-10, but less IL-6 and IL-12 p40, following LPS stimulation than BMDCs that received miR-146a À / À exosomes (Fig. 5d-f ). This gene expression profile demonstrates that miR-146a-containing exosomes reduce the pro-inflammatory response by BMDCs following LPS treatment. Without LPS treatment, there was no significant difference in IL-10, IL-6 or IL-12 p40 expression by cells receiving Wt versus miR-146a À / À exosomes ( Fig. 5d-f) , indicating that exosomal miR-146a specifically alters how these cells respond to LPS. Similar to miR-155, our data indicate that miR-146a is functionally transferred in exosomes and able to cause physiological changes in recipient cells. However, unlike miR-155, exosomal miR-146a acts to dampen the inflammatory response to LPS. These results are consistent with previous observations that miR-155 and miR-146a play opposing roles during inflammation 25, 31 .
miR-155 is transferred between immune cells in vivo. As we observed functional transfer of miRNAs in vitro, we wanted to determine whether miRNAs could be transferred between immune cells in vivo. We first investigated whether exosomes were present in mouse BM by isolating exosomes directly from the BM of Wt and miR-155 À / À mice using differential centrifugation. We found that both genotypes had exosomes present in the BM (Fig. 6a) , and that miR-155 was expressed in Wt BM exosomes (Fig. 6b) , whereas miR-146a was present in exosomes from both genotypes (Fig. 6c) . We next determined whether miR-155 was passed between immune cells in vivo. To investigate this, miR-155 À / À mice were lethally irradiated and reconstituted with either an equal mix of CD45.1 þ Wt and CD45.2 þ miR-155 À / À BM or just miR-155 À / À BM. After allowing 3 months for reconstitution, we injected mice with LPS to stimulate production of miR-155 by BM cells (Fig. 6d) . BM cells were isolated 24 h after LPS stimulation and miR-155 À / À haematopoietic cells were sorted via FACS according to their different CD45 alleles (Fig. 6f) . We also further fractionated the miR-155 À / À BM into B-cell, myeloid cell and T-cell fractions using the surface markers B220, CD11b and CD3, respectively (Fig. 6g,h ). Using qRT-PCR, we detected miR-155 expression in miR-155 À / À B cells, T cells and myeloid cells taken from miR-155 À / À mice that had been reconstituted with both Wt and miR-155 À / À BM (Fig. 6e) . As a control, no miR-155 expression was observed in cells from mice reconstituted with only miR-155 À / À BM. These data provide evidence that miR-155 is located within exosomes within the BM and is transferred between immune cells in vivo.
To determine whether miRNA-containing exosomes could deliver miRNAs to various cell types in vivo, we intraperitoneally (i.p.) injected B10 9 exosomes derived from miR-155 À / À or Wt BMDCs into miR-155 À / À mice. After multiple injections over a week, the spleens of these mice were harvested and CD3 þ T cells, B220 þ B cells and CD11b þ myeloid cells were sorted via FACS. We found that miR-155 was delivered to all three of these cell types in the spleen (Fig. 6i-k) . This indicates that exosomes are able to deliver miRNAs to various immune cell types.
Exosomal miR-155 enhances inflammatory responses in vivo.
Our in vitro data suggest that exosomally delivered miR-155 can increase the BMDC response to LPS (Fig. 5b) . Owing to these observations, we investigated whether we could see the same effect in vivo. Approximately 10 9 Wt or miR-155 À / À BMDCderived exosomes were i.p. injected into miR-155 À / À mice, followed by administration of LPS 24 h later and collection of serum 2 h after that (Fig. 7a) . The injection of Wt exosomes before LPS administration resulted in increased tumour necrosis factor-a (TNFa) and trending elevations in IL-6 serum concentrations compared with mice pretreated with miR-155 À / À exosomes (Fig. 7b,c) . In addition, we observed that miR-155 was delivered to the spleen, liver and BM, where we also found reduced target mRNA levels consistent with miR-155 activity in these tissues (Fig. 7d-i ). These data demonstrate that miR-155 can be functionally delivered to a variety of tissues and cell types via exosome injection, and that this can increase the response to LPS in vivo.
Exosomal miR-146a reduces inflammatory responses in vivo.
We next investigated whether exosomes containing miR-146a would have an anti-inflammatory impact following LPS administration to mice. Approximately 10 9 exosomes were isolated from Wt or miR-146a À / À BMDCs and injected i.p. into miR-146a À / À mice. Twenty-four hours later, the mice were given LPS and serum was collected after 2 h to assay inflammatory cytokine levels (Fig. 8a) . Mice having received Wt, miR-146a-containing exosomes had reduced TNFa and IL-6 serum concentrations after LPS administration compared with mice having received miR-146a-deficient exosomes (Fig. 8b,c) . Exosomes alone had a negligible effect on cytokine levels in vivo. Further, 24 h after LPS injection we isolated the spleen, liver and BM, and found that miR-146a was clearly present in these tissues from mice receiving Wt exosomes but was not present in tissues from mice that received miR-146a À / À exosomes (Fig. 8d-f ). In addition, miR-146a targets involved in Toll-like receptor (TLR) signalling were repressed in tissues in mice that received Wt exosomes (Fig. 8g-i) . Similar results were obtained when miR- ARTICLE 146a-containing exosomes were administered to Wt recipients ( Fig. 9a-i) . Together, these data demonstrate that exosomal miR146a can reduce the inflammatory response to LPS in mice.
Discussion
Although exosomes have been studied for a number of years, the biological roles of exosomal miRNAs are just beginning to be investigated [4] [5] [6] [7] [8] . Our data demonstrate that miRNAs 155 and 146a
are released from BMDCs in exosomes, are taken up by recipient BMDCs and subsequently mediate target gene repression. In addition, we have found that the transfer of miR-155 or miR-146a can alter the ability of recipient cells to respond to inflammatory cues both in vitro and in vivo. The capacity of these transferred miRNAs to influence the response of BMDCs to a proinflammatory stimulus suggests that the transfer of miRNAs is an important mechanism by which immune cells are primed to respond to an imminent encounter with a microbe. As miR-155 and miR-146a have been shown to regulate inflammation in a variety of contexts, our findings provide novel insights into how and where they function, providing a greater understanding of how they regulate mammalian immunity. Furthermore, our study adds to the growing body of evidence that miRNA transfer within exosomes is part of the intercellular communication networks that coordinates complex immune responses 8, 12, 14 .
Previous studies have used cell lines, miRNA overexpression and/or miRNA reporter constructs to study exosomal transfer of miRNAs [12] [13] [14] . Although these approaches have provided important evidence that miRNAs can be transferred in exosomes, we designed our approach to be as physiologically relevant as possible. miRNAs were produced at endogenous levels by primary cells and established endogenous miRNA target genes were used as readouts for miRNA activity in recipient cells. Furthermore, exosomes were purified away from other BMDC factors, such as cytokines, and miR-155-and miR-146a-deficient recipient cells were used to confidently track the delivery and specific effects of the exosomally delivered miRNA both in vitro and in vivo.
A recent report has claimed that the amounts of specific miRNAs contained within exosomes is less than one copy per exosome 35 . Our copy number analysis found there to be approximately one copy of miR-146a per exosome, consistent with exosomes having low content of individual miRNAs. However, we found that one BMDC produces B500 exosomes after 24 h of culture, indicating that each cell is able to release at least hundreds of copies of miR-146a in exosomes to be delivered to recipient BMDCs and mediate target knockdown. Thus, it seems that the large numbers of exosomes produced per cell allows for the loading of low miRNA numbers per exosome to achieve functional relevance.
It is important to note that exosome populations produced by Wt cells contain both miR-155 and miR-146a, which we show have either pro-or anti-inflammatory effects, respectively. There are several possible reasons why exosome populations would contain both of these functionally distinct miRNAs species. First, exosomes could be transferring both pro-and anti-inflammatory miRNAs together to buffer inflammatory responses by recipient cells, to achieve the optimal magnitude of response. Second, it is plausible that miR-155 and miR-146a are located in separate exosomes that are delivered to different target cell types. A third possibility is that miR-155 and miR-146a release in exosomes is a dynamically regulated process where the ratio of miR-155 to miR146a changes over time. For example, immune cells that have sensed a pathogen could initially release exosomes with high levels of pro-inflammatory miRNAs such as miR-155 followed by a shift to anti-inflammatory miRNAs such as miR-146a during the resolution phase of the response. These possibilities will be explored in future studies wherein the analysis of single exosomes may be required. Exosomes are clearly complex vesicles that contain an assortment of different membrane and soluble proteins, as well as different types of RNAs, including miRNAs 3 . Thus, we cannot formally rule out that exosomes produced by Wt versus miR-155 À / À or miR-146a À / À BMDCs may differ in some aspect other than the presence or the absence of the corresponding miRNA that has been genetically deleted, and that this may also have some influence on the inflammatory response by recipient cells. However, we have been able to address this possibility to some degree by successfully complementing the exosomal miRNA target gene phenotypes by loading miRNA mimics into miRNA knockout exosomes. Further, we were also able to demonstrate that target repression is direct through the use of seed mutant mimics that failed to repress target gene expression in recipient cells as well as 3 0 -UTR luciferase reporter assays where binding-site mutant 3 0 -UTRs were not repressed by exosomally transferred miRNAs. Collectively, these data strongly support the idea that individual miRNAs in exosomes are transferred between cells in a functionally relevant manner.
We also observed transfer of miRNAs between immune cells in vivo, indicating that this mechanism of cellular communication is also occurring in a physiologically relevant setting. Future work will be needed to isolate and study distinct cell types in the context of exosome production and uptake, as tissues such as the spleen, liver and BM are made up of a heterogeneous populations of cells that probably differ in their capacity to participate in these processes. Further, we predict that functional miRNA transfer via exosomes will be most relevant in defined microenvironments such as stem cell niches or within tumours, where exosome concentrations might be at their highest. Future studies will also require reagents where the production of miRNA-containing exosomes can be specifically blocked in vivo to assess the relevance of this mechanism in distinct inflammatory settings. Rab27 DKO mice will provide one such reagent despite possible roles for Rab27 a and b in exosomeindependent cellular processes. However, it is unclear whether the release of pro-or anti-inflammatory exosomal miRNAs will have a dominant impact on the inflammatory response in vivo, and we predict that this will probably be context dependent. However, as Rab27 DKO regulatory T cells have recently been shown to be functionally impaired, it is likely to be that these animals will have heightened inflammatory responses 23 . Consequently, the relevance of exosomal miRNA release by distinct immune cell types may have to be studied using cell-type-specific Rab27 DKO mice.
Exosomal miRNAs are currently being extensively studied as biomarkers of disease, as their serum levels are altered in a variety of pathological conditions [36] [37] [38] . Our results, in combination with others, suggest that these differences have functional consequences. As exosomes appear to be a natural way that cells transfer miRNAs, there is also growing interest in understanding the therapeutic potential of exosomes as delivery vehicles for specific miRNAs or their inhibitors [39] [40] [41] [42] [43] [44] . Producing exosomes from patients' own cells may serve as an ideal vehicle for autologous therapies involving miRNA delivery, and our capacity to load miRNA mimics suggests that the miRNA content of exosomes can be manipulated. Further, we clearly demonstrate that injection of ARTICLE miR-146a-and miR-155-containing exosomes results in delivery of these miRNAs to a variety of mouse tissues, repression of target genes and an altered inflammatory response in vivo, where miR-155 promoted and miR-146a repressed inflammation in response to endotoxin. This suggests that exosomal miR-146a could be used as a prophylaxis or therapy to treat inflammatory diseases, such as bacterial sepsis. Conversely, exosomal miR-155 could be used as an adjuvant to improve vaccine efficacy. However, it is also clear that the full spectrum of applications whereby exosomal miRNAs can be used is potentially quite broad and will require a great deal of future work. As we refine our understanding of how miRNAs are loaded into exosomes and delivered in a functional manner to specific recipient cells, such therapeutic approaches may become feasible in the clinic.
Methods
Mice. Cells culture. BMDCs were derived from mouse BM by culturing red blood celldepleted BM in complete RPMI (10% fetal bovine serum, 100 units per ml penicillin and 100 units per ml streptomycin, b-mercaptoethanol, glutamate, sodium pyruvate, HEPES and non-essential amino acids) with 20 ng ml À 1 granulocyte machrophage colony-stimulating factor for 3-4 days at 37°C with 5% CO 2 . The cells were then cultured in 5 ml complete RPMI with 20 ng ml À 1 granulocyte machrophage colony-stimulating factor for an additional 3-4 days for a total of 7 days in culture. LPS stimulation was performed at a concentration of 500 ng ml À 1 . Cells were separated using a Transwell Permeable Support 0.4 mm Polycarbonate Membrane 24 mm insert six-well plates (Costar).
RNA sequencing. Wt exosomes were transferred to recipient miR-155 and miR146a DKO BMDCs. Three biological replicates from Wt donor and exosomerecipient DKO BMDCs were submitted to the University of Utah's High Throughput Genomic Core for Illumina TrueSeq Small RNA Sample Prep. NTAs were identified and frequencies of A, G, C and U additions were calculated as described previously 17 by our bioinformatics core facility. In addition, we analysed each position in the mature miRNA sequences of miR-155 and miR-146a, and calculated the percentage of observed bases at each position to determine any changes in nucleotide composition between miRNAs in donor versus exosomerecipient BMDCs. RNA sequencing data are deposited in GEO with the accession number GSE67946.
Copy-number analysis. miRNA copy number was calculated in Wt and miR146a À / À donor cells, exosomes and miR-146a À / À BMDCs that received Wt exosomes. Total RNA was isolated (using the miRNeasy kit) from one million donor BMDCs and one million recipient BMDCs that were cultured with exosomes from one million donor BMDCs collected after 24 h or exosomes isolated from one million BMDCs after 24 h. Thirty nanograms of RNA isolated from these samples was then used for qRT-PCR analysis. To make a standard curve, 1 ng of synthetic single-stranded miR-146a (IDT custom RNA oligo-sequence: 5 0 -UGAGAACUG AAUUCCAUGGGUU-3 0 ) was spiked into either one million miR-146a À / À BMDCs or exosomes isolated from one million miR-146a À / À BMDCs, and total RNA was isolated in the same manner as our experimental samples (miRNeasy). Thirty nanograms of this isolated RNA was used to preform a complementary DNA reaction to use for standard curves. Standard curves for cells and exosomes were made with these cDNA samples via serial dilutions and cp values were determined via qPCR with miR-146a primers. The BMDC standard curve was then used to determine copy number in our cellular samples and the BMDC exosome standard curve was used to determine the copy number of miR-146a in our exosome samples.
Mimic. miRNA mimics were purchased from Qiagen. Scrambled, seed mutant and miR-mimic sequences are as follows: miR-146a scramble (5 0 -ACGAGUUACGUGGUACGUUAAU-3 0 ), miR-146a seed mutant (5 0 -UGUCAAGAGAAUUCCAUGGGUU-3 0 ), miR-146a mimic (5 0 -UGAGAACUGAAUUCCAUGGGUU-3 0 ), miR-155 scramble (5 0 -GGAUGUUAUUGCGUAUAUUAGGA-3 0 ), miR-155 seed mutant (5 0 -UUUGCUAAAAUUGUGAUAGGGGU-3 0 ) and miR-155 mimic (5 0 -UUAAUGCUAAUUGUGAUAGGGGU-3 0 ). Donor cells were transfected with 30 ml of the hi-perfect transfection reagent (Qiagen) in 2 ml of serum-free media with 60 ng of each mimic. After 24 h, cells were washed three times with PBS and given fresh medium. Exosomes were isolated 24 h after washing and transferred to recipient cells for 24 h.
Luciferase reporter assay. Knockout BMDCs (2.5 Â 10 5 ) were transfected with 3 0 -UTR luciferase reporter constructs (for mir-155 À / À : pmiReport, Bach1, Bach1 155 mutant, 2mer 29 ; (for miR-146 À / À : pmiReport, Traf6, Traf6 146a mutant 45 ) using Lonza's Amaxa Mouse Dendritic Cell Nucleofector Kit, according to manufacturer's instructions. After 6 h of nucleofection, BMDCs were treated with or without Wt BMDC-derived exosomes and luciferase activity was measured 24 h later using a Dual Luciferase Kit (Promega). Luciferase repression of exosometreated BMDCs compared with no exosome treatment was calculated and graphed as per cent change in luciferase activity. Renilla luciferase was used to normalize firefly luciferase values. 2 mg of each construct was transfected into BMDCs.
Exosome isolation and procedures. For in-vitro experiments, we isolated exosomes from approximately one million BMDCs cultured in media for 24 h and transferred them to the same number of recipient BMDCs. Differential centrifugation was performed to isolate exosomes from conditioned medium. Initial spins consisted of a 10-min spin at 1,000g, a 2,000g spin for 10 min and a 10,000g spin for 30 min. The supernatant was retained each time. The supernatant was then spun at 100,000g for 70 min and the pellet was re-suspended in 1 Â PBS, to dilute remaining soluble factors, followed by another centrifugation at 100,000g for 70 min. The final pellet contained the exosomes, which were re-suspended in tissue culture media. This protocol is based on previous exosome isolation methods 46 . We used either a Beckman ultracentrifuge with a TI75 fixed angle rotor or a Thermo Scientific Sorvall Lynx 6000 with a T26-8 Â 50 rotor. GW4869 is a neutral sphingomyelinase 2 inhibitor that has been previously used to prevent exosome release 13, 15 . In some experiments, we treated BMDCs with 10 mM GW4869 (Sigma-Aldrich) or vehicle for 24 h.
Exosome numbers for the miR-146a and miR-155 in-vivo experiments were determined using the EXOCET Exosome Quantification Assay Kit from System Biosciences, according to kit instructions. Three plates of approximately three million BMDCs each were cultured in media for 3 days. The supernatant from these plates was collected and exosomes were isolated as described above.
Western blotting and enzyme-linked immunosorbent assay. Protein was isolated with RIPA lysis buffer (RIPA buffer, phenylmethyl sulfonyl fluoride, NaF, NaVO 4 and protease inhibitor). Total protein levels were quantified using a Bio-Rad protein assay and equal amounts of protein were loaded and separated using 12% (TRAF6, Ago2 and CD63) or 8% (SHIP1 and IRAK1) SDS-PAGE followed by immunoblotting with appropriate antibodies. Antibodies include the following: a-TRAF6 at 1:500 dilution (EP591Y Abcam, ab33915), a-b-actin antibody at 1:1,000 dilution (mAbcam 8226, ab8226), a-Ago2/eIF2C2 antibody at 1:200 dilution (Abcam, ab32381), a-CD63 (H-193) at 1:200 dilution (Santa Cruz Biotechnology, sc-15363), a-SHIP1 (V-19) at 1:250 dilution (Santa Cruz Biotechnology, sc-1963), and a-IRAK1 D5167 at 1:500 Dilution (Cell Signaling, 4504). Western blottings were quantified using ImageJ software. The enzyme-linked immunosorbent assay used to quantify mouse IL-6 and TNFa concentrations were obtained from eBioscience and were performed using the manufacturer's suggested protocol. Images have been cropped for presentation. Full-size images are presented in Supplementary Figs 7-9 .
RNA isolation and qRT-PCR. RNA isolation was performed using Qiagen's miRNeasy kit, according to manufacturer's instructions. Mature miRNA cDNA was made with a miRCURY LNA universal RT miRNA PCR kit using 10 ng of RNA from each sample (Exiqon). qPCR of mature miRNA was performed with the miRCURY LNA universal RT miRNA PCR kit SYBR green master mix (Exiqon) with LNA primers for miR-146a-5p (Exiqon), mmu-miR155-5p (Exiqon), mmumiR-425-5p (Exiqon) and 5s rRNA (Exiqon). Custom LNA primers were also made and designed by Exiqon to detect the miR-155 and miR-146a seed mutant mimics (miR-146a design ID 410833-1) (miR-155 design ID 410829-1). 5s was used to normalize expression. cDNA from total RNA was made with qScript using 30 ng of RNA from each sample (Quanta). qPCR was performed with Promega GoTaq pPCR master mix. Primer sequences are as follows: SHIP1-F ( . L32 levels were used to normalize mRNA expression levels.
Electron microscopy. EM samples were prepared using differential centrifugation from BMDC-conditioned media. Exosomal pellets were re-suspended in PBS and processed by the University of Utah's EM core facility for cryo-EM analysis.
Immunoprecipitations. An anti-pan Ago antibody (clone 2A8, Millipore) was was used to IP Ago proteins. a-AGO and IgG control coated beads were prepared by incubating magnetic protein G beads (Active motif) with each respective antibody in IP lysis buffer (0.5% NP40, 150 mM KCl, 1 mM NaF, 25 mM Tris, 2 mM EDTA, protease inhibitor and 0.5 mM dithiothreitol) with rotation overnight at 4°C. Onethird of the protein lysate prepared from BMDCs that had received either Wt or miR-155 À / À exosomes using IP lysis buffer was used for the IP. Bead-antibody mixes were washed three times with lysis buffer with rotation at 4°C, re-suspended in lysis buffer and added to the lysates. Lysates were incubated with bead-antibody mix at 4°C with rotation overnight and then washed six times with IP wash buffer (300 mM NaCl, 50 mM Tris,.01% NP40, 5 mM MgCl 2 , 129 ml dH 2 O), with the last wash done using PBS. Protein was isolated from a fraction of the sample with 1 Â Laemmli diluted in lysis buffer and RNA was isolated from another fraction using miRNeasy extraction. A western blotting for AGO2 (Abcam) and qRT-PCR analysis for miR-155 and miR-146a were performed to confirm AGO pulldown and association with these miRNAs.
Flow cytometry. Fluorophore-conjugated monoclonal antibodies specific to CD45.1, CD45.2, B220, CD3, CD11b or CD11c (Biolegend) were used to stain red blood cell-depleted BM and spleen cells. These populations were sorted using a FACS Aria II in the Flow Cytometry Core Facility at the University of Utah.
Statistics. Data were analysed using Student's t-tests, to determine statistically significant differences between relevant samples. P-values were either listed or represented by the following number of asterisks: *Po0.05; **Po0.01; ***Po0.001; ****Po0.0001. 
